European Commission approves Evrysdi for the treatment of 5qSMA

Following our request for regular updates, Roche is delighted to inform us that today the European Commission (EC) approved Evrysdi™ (risdiplam), the first and only at home treatment for SMA, with proven efficacy in adults, children and babies two months and older. Risdiplam was reviewed under the European Medicine Agency’s (EMA) accelerated assessment programme, intended … Continue reading European Commission approves Evrysdi for the treatment of 5qSMA